Literature DB >> 27133138

The (68)Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma).

Stephane Chauvie1, Fabrizio Bergesio2, Federica Fioroni3, Marco Brambilla4, Alberto Biggi2, Annibale Versari3, Luca Guerra5, Giovanni Storto6, Pellegrino Musto6, Stefano Luminari7, Maria G Cabras8, Monica Balzarotti9, Luigi Rigacci10, Maurizio Martelli11, Umberto Vitolo12, Massimo Federico7, Andrea Gallamini13.   

Abstract

PURPOSE: The quantitative assessment of Positron Emission Tomography (PET) scans using standardized uptake value and derived parameters proved to be superior to traditional qualitative assessment in several retrospective or mono-centric prospective reports. Since different scanners give different quantitative readings, a program for clinical trial qualification (CTQ) is mandatory to guarantee a reliable and reproducible use of quantitative PET in prospective multi-centre clinical trials and in every-day clinical life.
METHODS: We set up, under the auspices of Italian Foundation on Lymphoma (FIL), a CTQ program consisting of the PET/CT scan acquisition and analysis of (18)F and (68)Ge NEMA/IEC image quality phantoms for the reduction of inter-scanner variability. Variability was estimated on background activity concentration (BAC) and sphere to background ratio (SBR).
RESULTS: The use of a (68)Ge phantom allowed reducing the inter-scanner variability among different scanners from 74.0% to 20.5% in BAC and from 63.3% to 17.4% in SBR compared to using the (18)F phantom. The CTQ criteria were fulfilled at first round in 100% and 28% of PET scanners with (68)Ge and (18)F respectively.
CONCLUSIONS: The (68)Ge phantom proved a reliable tool for PET scanner qualification, able to significantly reduce the potential sources of error while increasing the reproducibility of PET derived quantitative parameter measurement.
Copyright © 2016 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clinical trials; Lymphoma; Positron emission tomography; Quantitative imaging

Mesh:

Substances:

Year:  2016        PMID: 27133138     DOI: 10.1016/j.ejmp.2016.04.004

Source DB:  PubMed          Journal:  Phys Med        ISSN: 1120-1797            Impact factor:   2.685


  5 in total

1.  Measuring temporal stability of positron emission tomography standardized uptake value bias using long-lived sources in a multicenter network.

Authors:  Darrin Byrd; Rebecca Christopfel; Grae Arabasz; Ciprian Catana; Joel Karp; Martin A Lodge; Charles Laymon; Eduardo G Moros; Mikalai Budzevich; Sadek Nehmeh; Joshua Scheuermann; John Sunderland; Jun Zhang; Paul Kinahan
Journal:  J Med Imaging (Bellingham)       Date:  2018-01-04

2.  Evaluation of Cross-Calibrated 68Ge/68Ga Phantoms for Assessing PET/CT Measurement Bias in Oncology Imaging for Single- and Multicenter Trials.

Authors:  Darrin W Byrd; Robert K Doot; Keith C Allberg; Lawrence R MacDonald; Wendy A McDougald; Brian F Elston; Hannah M Linden; Paul E Kinahan
Journal:  Tomography       Date:  2016-12

Review 3.  The Strategies to Homogenize PET/CT Metrics: The Case of Onco-Haematological Clinical Trials.

Authors:  Stephane Chauvie; Fabrizio Bergesio
Journal:  Biomedicines       Date:  2016-11-15

4.  Evaluation of PET quantitation accuracy among multiple discovery IQ PET/CT systems via NEMA image quality test.

Authors:  Delphine Vallot; Elena De Ponti; Sabrina Morzenti; Anna Gramek; Anna Pieczonka; Gabriel Reynés Llompart; Jakub Siennicki; Paul Deak; Chiranjib Dutta; Jorge Uribe; Olivier Caselles
Journal:  EJNMMI Phys       Date:  2020-05-12

5.  Does a 6-point scale approach to post-treatment 18F-FDG PET-CT allow to improve response assessment in head and neck squamous cell carcinoma? A multicenter study.

Authors:  P Bonomo; A Merlotti; S Morbelli; V Berti; C Saieva; F Bergesio; A Bacigalupo; L Belgioia; C Franzese; E Lopci; A Casolo; E D'Angelo; D Alterio; L Travaini; L Berretta; V Pirro; S Ursino; D Volterrani; M Roncali; F Vigo; S Cicchetti; F Scalone; G Belli; S Cauda; I Desideri; E Russi; L Livi; A Bianchi
Journal:  Eur J Hybrid Imaging       Date:  2020-05-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.